Status: Recruiting
CRUZ Tunisia-Multivessel Registry
The primary objective of this registry is to evaluate the safety and clinical performance of the biodegradable polymer-coated Supraflex Cruz Sirolimus-eluting Stent (SES) in an unselected, all-comer patient population with multivessel disease. This population represents daily clinical practice and includes patients requiring coronary revascularization with drug-eluting stents (DES).
Participants needed: 1,000
Trial details
Age: 18-99Biological sex: AllType: ObservationalSponsor: Sahajanand Medical Technologies LimitedUpdated: Apr 27, 2026Locations: 2Duration: 12 Months
Eligibility criteria
Patient must be at least 18 years of age [+3]
Women with known pregnancy or who are lactating [+3]